Scaricare la presentazione
La presentazione è in caricamento. Aspetta per favore
1
Assessing the role of eptifibatide in patients with diffuse coronary disease undergoing drug-eluting stenting: The INtegrilin plus STenting to Avoid myocardial Necrosis Trial Giuseppe Biondi-Zoccai, MD, Marco Valgimigli, MD, PhD, Massimo Margheri, MD, Antonio Marzocchi, MD, Corrado Lettieri, MD, Amerigo Stabile, MD, A. Sonia Petronio, MD, Giorgio Binetti, MD, Leonardo Bolognese, MD, Pietro Bellone, MD, Gennaro Sardella, MD, Marco Contarini, MD, Imad Sheiban, MD, Sebastiano Marra, MD, Federico Piscione, MD, Francesco Romeo, MD, Antonio Colombo, MD, Giuseppe Sangiorgi, MD American Heart Journal Volume 163, Issue 5, Pages 835.e1-835.e7 (May 2012) DOI: /j.ahj Copyright © 2012 Mosby, Inc. Terms and Conditions
2
Figure 1 Flow diagram of the study.
American Heart Journal , 835.e1-835.e7DOI: ( /j.ahj ) Copyright © 2012 Mosby, Inc. Terms and Conditions
3
Figure 2 Changes in serum levels of CK-MB after PCI.
American Heart Journal , 835.e1-835.e7DOI: ( /j.ahj ) Copyright © 2012 Mosby, Inc. Terms and Conditions
4
Figure 3 Changes in serum levels of cardiac troponin T after PCI.
American Heart Journal , 835.e1-835.e7DOI: ( /j.ahj ) Copyright © 2012 Mosby, Inc. Terms and Conditions
5
Figure 4 Survival free from MACEs, showing similar results for the eptifibatide and placebo groups (P = .7 at log-rank test). American Heart Journal , 835.e1-835.e7DOI: ( /j.ahj ) Copyright © 2012 Mosby, Inc. Terms and Conditions
Presentazioni simili
